Suspension of trading
Exscientia plc Stock
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
04:00:00 2024-11-19 pm EST
|
5-day change | 1st Jan Change | ||
| 4.840 USD | +3.20% |
|
-.--% | - |
| 24-11-20 | Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index | CI |
| 24-11-20 | Recursion Pharmaceuticals, Exscientia Complete Business Combination | MT |
| Market Cap | 500M 680M 583M 545M 940M 65.01B 955M 6.43B 2.52B 32.6B 2.55B 2.5B 108B | P/E 2022 |
-4.55x | P/E 2023 | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 156M 212M 182M 170M 293M 20.25B 298M 2B 784M 10.16B 796M 778M 33.58B | EV / Sales 2022 |
1.9x | EV / Sales 2023 | 14.2x |
| Free-Float |
36.87% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +3.20% |
| 3 years | 3.8 | 7.91 | |
| 5 years | 3.8 | 30.38 | |
| 10 years | 3.8 | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 61 | 2024-06-05 | |
| Chief Tech/Sci/R&D Officer | - | 2022-04-30 | |
John Overington
CTO | Chief Tech/Sci/R&D Officer | - | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 63 | 2017-09-27 |
Robert Ghenchev
BRD | Director/Board Member | 43 | 2020-04-30 |
Elizabeth Crain
CHM | Chairman | 61 | 2024-02-11 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.20% | -.--% | -.--% | -24.02% | 633M | ||
| +2.37% | +2.30% | +3.39% | +22.74% | 48.63B | ||
| -0.62% | +4.58% | +487.47% | +624.71% | 46.3B | ||
| +2.09% | +4.96% | +20.59% | +95.21% | 41.97B | ||
| +3.85% | +3.13% | +29.60% | +16.50% | 39.51B | ||
| -0.72% | -3.91% | +17.87% | +47.98% | 31.75B | ||
| +3.04% | +1.89% | +31.62% | +143.62% | 16.48B | ||
| +4.33% | +1.63% | - | - | 16.34B | ||
| +1.44% | +1.52% | +4.22% | +31.00% | 14B | ||
| +3.87% | +1.98% | +82.99% | +45.80% | 13.33B | ||
| Average | +2.29% | +0.94% | +75.31% | +111.50% | 26.89B | |
| Weighted average by Cap. | +1.85% | +0.96% | +106.97% | +156.75% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.22M 37.04M 31.78M 29.67M 51.19M 3.54B 52.04M 350M 137M 1.78B 139M 136M 5.87B | 20.08M 27.32M 23.44M 21.89M 37.76M 2.61B 38.38M 258M 101M 1.31B 103M 100M 4.33B |
| Net income | -119M -162M -139M -129M -223M -15.44B -227M -1.53B -598M -7.74B -607M -593M -25.61B | -146M -199M -170M -159M -274M -18.98B -279M -1.88B -735M -9.52B -746M -730M -31.48B |
| Net Debt | -492M -669M -574M -536M -925M -63.98B -940M -6.33B -2.48B -32.09B -2.51B -2.46B -106B | -344M -468M -402M -375M -647M -44.76B -658M -4.43B -1.73B -22.45B -1.76B -1.72B -74.22B |
Employees
483
- Stock Market
- Stocks
- EXAI Stock
Select your edition
All financial news and data tailored to specific country editions
















